Drug Trial Radar · NCT07856225
Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
370
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Jun 1, 2027
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- Fundación Santa Fe de BogotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 2, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Breast cancer is the most common cancer in women worldwide. Its molecular classification, based on hormone receptors (estrogen and progesterone), HER2 and Ki-67, defines subtypes with different prognoses and treatments. In Colombia, there is limited information that integrates the clinical, treatment, sociodemographic and contextual characteristics of each subtype, and limited data on the direct medical costs of breast cancer care. This retrospective cohort study will review the medical records of women 18 years or older with biopsy-confirmed breast cancer and a documented molecular subtype who were treated at Fundación Santa Fe de Bogotá (Bogotá, Colombia) between January 1, 2014 and December 31, 2024. It will describe each molecular subtype (luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-enriched, triple-negative and HER2-low) and evaluate the association of clinical, molecular and treatment characteristics with overall survival, progression-free survival, recurrence, treatment response and grade 3-4 adverse events. It will also explore the impact of the COVID-19 pandemic and health insurance regimen on outcomes, and estimate direct medical costs of breast cancer care by clinical stage and phase of care. The investigators will not assign or modify any treatment.
Conditions
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- HER2-Positive Breast Cancer
- Hormone Receptor-Positive Breast Cancer
Interventions
CDK4/6 InhibitorsDrug
CDK4/6 inhibitors (palbociclib, ribociclib or abemaciclib) combined with endocrine therapy, administered in routine clinical practice. The study does not assign or modify treatment; exposure data are abstracted retrospectively from medical records.
Anti-HER2 TherapyDrug
HER2-targeted therapy (such as trastuzumab, pertuzumab or trastuzumab emtansine) administered in routine clinical practice. The study does not assign or modify treatment.
Standard Breast Cancer TreatmentOther
Surgery, radiotherapy, chemotherapy, endocrine therapy and other systemic therapies administered according to routine clinical practice. The study does not assign or modify treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From diagnosis until death from any cause or last follow-up, assessed up to approximately 12 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Universitario Fundación Santa Fe de Bogotá
Bogotá, Bogota D.C., Colombia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.